GlassScriptPhysician profile
Neda Ebrahimi
NPI 1679033781
$10,563.89
in general payments reported to CMS, 2019-2025
31 companies · $5,193 in 2025
The $5,193 reported for 2025 was more than what 87% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $90.07 · 2023: $1,050 · 2024: $4,231 · 2025: $5,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,574 · Travel and Lodging: $875 · Education: $24.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,574.24 |
| Travel and Lodging | $874.94 |
| Education | $24.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,727.04 | 2023-2025 | Minimed 780g |
| Abbott Laboratories | $997.56 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $874.30 | 2024-2025 | |
| Amgen INC. | $849.06 | 2024-2025 | Evenity, Repatha, Prolia |
| Corcept Therapeutics | $692.95 | 2023-2025 | Korlym |
| Novo Nordisk INC | $675.07 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Alexion Pharmaceuticals, INC. | $594.99 | 2024-2025 | Strensiq, Kanuma |
| Insulet Corporation | $489.53 | 2024-2025 | Omnipod, Omnipod |
| Dexcom, INC. | $473.53 | 2023-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Bayer Healthcare Pharmaceuticals INC. | $456.76 | 2024-2025 | |
| Beta Bionics, INC. | $334.67 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Cequr Corporation | $327.95 | 2024-2025 | Cequr Simplicity |
| Madrigal Pharmaceuticals | $327.58 | 2024-2025 | Rezdiffra, Resmetirom |
| Kyowa Kirin, INC. | $323.97 | 2024-2025 | Crysvita |
| Lilly USA, LLC | $240.31 | 2020-2025 | Zepbound, Mounjaro |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $163.27 | 2025 | |
| Chiesi USA, INC. | $147.10 | 2025 | Mycapssa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.55 | 2024 | Jardiance |
| Recordati_rare_diseases_inc. | $134.58 | 2025 | Isturisa |
| Sequel Med Tech, LLC | $117.25 | 2025 | Twiist |
| Tandem Diabetes Care, INC. | $85.95 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amphastar Pharmaceuticals, INC. | $73.75 | 2025 | |
| Xeris Pharmaceuticals, INC. | $63.92 | 2025 | Gvoke Hypopen, Recorlev |
| Almatica Pharma LLC | $55.06 | 2024-2025 | Teriparatide |
| Radius Health, INC. | $53.45 | 2025 | Tymlos |
| Mannkind Corporation | $34.48 | 2024 | |
| Ibsa Pharma INC. | $31.56 | 2024-2025 | Licart, Tirosint, Flector |
| Amneal Pharmaceuticals LLC | $30.67 | 2025 | Unithroid |
| Ascendis Pharma Endocrinology INC | $23.40 | 2025 | Yorvipath |
| Astellas Pharma US INC | $15.28 | 2025 | Veozah |
| Millicent US INC | $13.35 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neda Ebrahimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.